APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neoantigen Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neoantigen Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025195 pages

Choose your research edition.

Industry ResearchNeoantigen Vaccine Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Neoantigen Vaccine Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Neoantigen Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neoantigen Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Neoantigen Vaccine Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Neoantigen Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Neoantigen Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neoantigen Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neoantigen Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neoantigen Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neoantigen Vaccine include Merck & Co Inc, Eli Lilly and Company, Pfizer, ZIOPHARM Oncology, Vaximm AG, Vaccibody AS, Roche Holding AG, OSE Immunotherapeutics and Novogene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Neoantigen Vaccine market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neoantigen Vaccine and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neoantigen Vaccine revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neoantigen Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Neoantigen Vaccine Segment by Company

Merck & Co Inc

Eli Lilly and Company

Pfizer

ZIOPHARM Oncology

Vaximm AG

Vaccibody AS

Roche Holding AG

OSE Immunotherapeutics

Novogene

Nouscom

Moderna

Medigene AG

ISA Pharmaceuticals

Gritstone Bio

Genocea Biosciences Inc

BrightPath Biotherapeutics

BioNTech

Avidea Technologies

Agenus Inc

Advaxis

Neoantigen Vaccine Segment by Type

Personalized Vaccine

Off-the shelf Vaccine

Neoantigen Vaccine Segment by Application

Gastrointestinal Cancer

Lung Cancer

Melanoma Cancer

Brain Cancer

Others

Neoantigen Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neoantigen Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neoantigen Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neoantigen Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neoantigen Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neoantigen Vaccine industry.

Chapter 3: Detailed analysis of Neoantigen Vaccine companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neoantigen Vaccinerevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neoantigen Vaccine Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Personalized Vaccine Table 3. Key Players of Off-the shelf Vaccine Table 4. Global Neoantigen Vaccine Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Gastrointestinal Cancer Table 6. Key Players of Lung Cancer Table 7. Key Players of Melanoma Cancer Table 8. Key Players of Brain Cancer Table 9. Key Players of Others Table 10. Global Neoantigen Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global Neoantigen Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 12. Global Neoantigen Vaccine Market Share by Region (2021-2026) Table 13. Global Neoantigen Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 14. Global Neoantigen Vaccine Market Share by Region (2027-2032) Table 15. Neoantigen Vaccine Industry Trends Table 16. Neoantigen Vaccine Industry Drivers Table 17. Neoantigen Vaccine Industry Opportunities and Challenges Table 18. Neoantigen Vaccine Industry Restraints Table 19. Global Neoantigen Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 20. Global Neoantigen Vaccine Revenue Market Share by Company (2021-2026) Table 21. Global Neoantigen Vaccine Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global Neoantigen Vaccine Key Company Head Office and Area Served Table 23. Global Neoantigen Vaccine Company, Product Type & Application Table 24. Global Neoantigen Vaccine Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global Neoantigen Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global Neoantigen Vaccine Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Neoantigen Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 29. Global Neoantigen Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 30. Global Neoantigen Vaccine Revenue Market Share by Type (2021-2026) Table 31. Global Neoantigen Vaccine Revenue Market Share by Type (2027-2032) Table 32. Global Neoantigen Vaccine Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Neoantigen Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 34. Global Neoantigen Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 35. Global Neoantigen Vaccine Revenue Market Share by Application (2021-2026) Table 36. Global Neoantigen Vaccine Revenue Market Share by Application (2027-2032) Table 37. Merck & Co Inc Company Information Table 38. Merck & Co Inc Business Overview Table 39. Merck & Co Inc Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Merck & Co Inc Neoantigen Vaccine Product Portfolio Table 41. Merck & Co Inc Recent Development Table 42. Eli Lilly and Company Company Information Table 43. Eli Lilly and Company Business Overview Table 44. Eli Lilly and Company Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Eli Lilly and Company Neoantigen Vaccine Product Portfolio Table 46. Eli Lilly and Company Recent Development Table 47. Pfizer Company Information Table 48. Pfizer Business Overview Table 49. Pfizer Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Pfizer Neoantigen Vaccine Product Portfolio Table 51. Pfizer Recent Development Table 52. ZIOPHARM Oncology Company Information Table 53. ZIOPHARM Oncology Business Overview Table 54. ZIOPHARM Oncology Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. ZIOPHARM Oncology Neoantigen Vaccine Product Portfolio Table 56. ZIOPHARM Oncology Recent Development Table 57. Vaximm AG Company Information Table 58. Vaximm AG Business Overview Table 59. Vaximm AG Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Vaximm AG Neoantigen Vaccine Product Portfolio Table 61. Vaximm AG Recent Development Table 62. Vaccibody AS Company Information Table 63. Vaccibody AS Business Overview Table 64. Vaccibody AS Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Vaccibody AS Neoantigen Vaccine Product Portfolio Table 66. Vaccibody AS Recent Development Table 67. Roche Holding AG Company Information Table 68. Roche Holding AG Business Overview Table 69. Roche Holding AG Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Roche Holding AG Neoantigen Vaccine Product Portfolio Table 71. Roche Holding AG Recent Development Table 72. OSE Immunotherapeutics Company Information Table 73. OSE Immunotherapeutics Business Overview Table 74. OSE Immunotherapeutics Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. OSE Immunotherapeutics Neoantigen Vaccine Product Portfolio Table 76. OSE Immunotherapeutics Recent Development Table 77. Novogene Company Information Table 78. Novogene Business Overview Table 79. Novogene Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Novogene Neoantigen Vaccine Product Portfolio Table 81. Novogene Recent Development Table 82. Nouscom Company Information Table 83. Nouscom Business Overview Table 84. Nouscom Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Nouscom Neoantigen Vaccine Product Portfolio Table 86. Nouscom Recent Development Table 87. Moderna Company Information Table 88. Moderna Business Overview Table 89. Moderna Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Moderna Neoantigen Vaccine Product Portfolio Table 91. Moderna Recent Development Table 92. Medigene AG Company Information Table 93. Medigene AG Business Overview Table 94. Medigene AG Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 95. Medigene AG Neoantigen Vaccine Product Portfolio Table 96. Medigene AG Recent Development Table 97. ISA Pharmaceuticals Company Information Table 98. ISA Pharmaceuticals Business Overview Table 99. ISA Pharmaceuticals Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 100. ISA Pharmaceuticals Neoantigen Vaccine Product Portfolio Table 101. ISA Pharmaceuticals Recent Development Table 102. Gritstone Bio Company Information Table 103. Gritstone Bio Business Overview Table 104. Gritstone Bio Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 105. Gritstone Bio Neoantigen Vaccine Product Portfolio Table 106. Gritstone Bio Recent Development Table 107. Genocea Biosciences Inc Company Information Table 108. Genocea Biosciences Inc Business Overview Table 109. Genocea Biosciences Inc Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 110. Genocea Biosciences Inc Neoantigen Vaccine Product Portfolio Table 111. Genocea Biosciences Inc Recent Development Table 112. BrightPath Biotherapeutics Company Information Table 113. BrightPath Biotherapeutics Business Overview Table 114. BrightPath Biotherapeutics Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 115. BrightPath Biotherapeutics Neoantigen Vaccine Product Portfolio Table 116. BrightPath Biotherapeutics Recent Development Table 117. BioNTech Company Information Table 118. BioNTech Business Overview Table 119. BioNTech Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 120. BioNTech Neoantigen Vaccine Product Portfolio Table 121. BioNTech Recent Development Table 122. Avidea Technologies Company Information Table 123. Avidea Technologies Business Overview Table 124. Avidea Technologies Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 125. Avidea Technologies Neoantigen Vaccine Product Portfolio Table 126. Avidea Technologies Recent Development Table 127. Agenus Inc Company Information Table 128. Agenus Inc Business Overview Table 129. Agenus Inc Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 130. Agenus Inc Neoantigen Vaccine Product Portfolio Table 131. Agenus Inc Recent Development Table 132. Advaxis Company Information Table 133. Advaxis Business Overview Table 134. Advaxis Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 135. Advaxis Neoantigen Vaccine Product Portfolio Table 136. Advaxis Recent Development Table 137. North America Neoantigen Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 138. North America Neoantigen Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 139. North America Neoantigen Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 140. North America Neoantigen Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 141. North America Neoantigen Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. North America Neoantigen Vaccine Market Size by Country (2021-2026) Table 143. North America Neoantigen Vaccine Market Size by Country (2027-2032) Table 144. Europe Neoantigen Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 145. Europe Neoantigen Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 146. Europe Neoantigen Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 147. Europe Neoantigen Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 148. Europe Neoantigen Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Europe Neoantigen Vaccine Market Size by Country (2021-2026) Table 150. Europe Neoantigen Vaccine Market Size by Country (2027-2032) Table 151. China Neoantigen Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 152. China Neoantigen Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 153. China Neoantigen Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 154. China Neoantigen Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 155. Asia Neoantigen Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 156. Asia Neoantigen Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 157. Asia Neoantigen Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 158. Asia Neoantigen Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 159. Asia Neoantigen Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Asia Neoantigen Vaccine Market Size by Country (2021-2026) Table 161. Asia Neoantigen Vaccine Market Size by Country (2027-2032) Table 162. South America, Middle East & Africa Neoantigen Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 163. South America, Middle East & Africa Neoantigen Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 164. South America, Middle East & Africa Neoantigen Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 165. South America, Middle East & Africa Neoantigen Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 166. South America, Middle East & Africa Neoantigen Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. South America, Middle East & Africa Neoantigen Vaccine Market Size by Country (2021-2026) Table 168. South America, Middle East & Africa Neoantigen Vaccine Market Size by Country (2027-2032) Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Neoantigen Vaccine Product Image Figure 2. Global Neoantigen Vaccine Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Neoantigen Vaccine Market Share by Type: 2025 VS 2032 Figure 4. Personalized Vaccine Image Figure 5. Off-the shelf Vaccine Image Figure 6. Global Neoantigen Vaccine Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Neoantigen Vaccine Market Share by Application: 2025 VS 2032 Figure 8. Gastrointestinal Cancer Image Figure 9. Lung Cancer Image Figure 10. Melanoma Cancer Image Figure 11. Brain Cancer Image Figure 12. Others Image Figure 13. Global Neoantigen Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 15. Global Neoantigen Vaccine Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Neoantigen Vaccine Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Neoantigen Vaccine Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Neoantigen Vaccine Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Neoantigen Vaccine Revenue Market Share by Type (2021-2032) Figure 22. Global Neoantigen Vaccine Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Neoantigen Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 25. North America Neoantigen Vaccine Market Share by Type (2021-2032) Figure 26. North America Neoantigen Vaccine Market Share by Application (2021-2032) Figure 27. North America Neoantigen Vaccine Market Share by Country (2021-2032) Figure 28. United States Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 29. Canada Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 31. Europe Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 32. Europe Neoantigen Vaccine Market Share by Type (2021-2032) Figure 33. Europe Neoantigen Vaccine Market Share by Application (2021-2032) Figure 34. Europe Neoantigen Vaccine Market Share by Country (2021-2032) Figure 35. Germany Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 36. France Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 38. Italy Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 39. Russia Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 41. China Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 42. China Neoantigen Vaccine Market Share by Type (2021-2032) Figure 43. China Neoantigen Vaccine Market Share by Application (2021-2032) Figure 44. Asia Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 45. Asia Neoantigen Vaccine Market Share by Type (2021-2032) Figure 46. Asia Neoantigen Vaccine Market Share by Application (2021-2032) Figure 47. Asia Neoantigen Vaccine Market Share by Country (2021-2032) Figure 48. Japan Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 52. India Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 53. Australia Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Neoantigen Vaccine Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Neoantigen Vaccine Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Neoantigen Vaccine Market Share by Country (2021-2032) Figure 58. Brazil Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 63. UAE Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 65. Chile Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Personalized Vaccine
  • Off-the shelf Vaccine
Applications
  • Gastrointestinal Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Brain Cancer
  • Others
Companies covered
  • Merck & Co Inc
  • Eli Lilly and Company
  • Pfizer
  • ZIOPHARM Oncology
  • Vaximm AG
  • Vaccibody AS
  • Roche Holding AG
  • OSE Immunotherapeutics
  • Novogene
  • Nouscom
  • Moderna
  • Medigene AG
  • ISA Pharmaceuticals
  • Gritstone Bio
  • Genocea Biosciences Inc
  • BrightPath Biotherapeutics
  • BioNTech
  • Avidea Technologies
  • Agenus Inc
  • Advaxis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Neoantigen Vaccine Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Personalized Vaccine
  5. 1.2.3 Off-the shelf Vaccine
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Neoantigen Vaccine Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Gastrointestinal Cancer
  9. 1.3.3 Lung Cancer
  10. 1.3.4 Melanoma Cancer
  11. 1.3.5 Brain Cancer
  12. 1.3.6 Others
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Neoantigen Vaccine Growth Trends by Region
  15. 1.5.1 Global Neoantigen Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Neoantigen Vaccine Market Size by Region (2021-2026)
  17. 1.5.3 Neoantigen Vaccine Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Neoantigen Vaccine Market Dynamics
  1. 2.1 Neoantigen Vaccine Industry Trends
  2. 2.2 Neoantigen Vaccine Industry Drivers
  3. 2.3 Neoantigen Vaccine Industry Opportunities and Challenges
  4. 2.4 Neoantigen Vaccine Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Neoantigen Vaccine Revenue by Company (2021-2026)
  2. 3.2 Global Neoantigen Vaccine Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Neoantigen Vaccine Key Company Head office and Area Served
  4. 3.4 Global Neoantigen Vaccine Company, Product Type & Application
  5. 3.5 Global Neoantigen Vaccine Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Neoantigen Vaccine Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Neoantigen Vaccine Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Neoantigen Vaccine Tier 1, Tier 2, and Tier 3
4 Neoantigen Vaccine Market by Type
  1. 4.1 Global Neoantigen Vaccine Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Neoantigen Vaccine Market Size by Type (2021-2032)
  3. 4.3 Global Neoantigen Vaccine Market Size Share by Type (2021-2032)
5 Neoantigen Vaccine Market by Application
  1. 5.1 Global Neoantigen Vaccine Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Neoantigen Vaccine Market Size by Application (2021-2032)
  3. 5.3 Global Neoantigen Vaccine Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Merck & Co Inc
  2. 6.1.1 Merck & Co Inc Company Information
  3. 6.1.2 Merck & Co Inc Business Overview
  4. 6.1.3 Merck & Co Inc Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Merck & Co Inc Neoantigen Vaccine Product Portfolio
  6. 6.1.5 Merck & Co Inc Recent Developments
  7. 6.2 Eli Lilly and Company
  8. 6.2.1 Eli Lilly and Company Company Information
  9. 6.2.2 Eli Lilly and Company Business Overview
  10. 6.2.3 Eli Lilly and Company Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Eli Lilly and Company Neoantigen Vaccine Product Portfolio
  12. 6.2.5 Eli Lilly and Company Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Pfizer Neoantigen Vaccine Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 ZIOPHARM Oncology
  20. 6.4.1 ZIOPHARM Oncology Company Information
  21. 6.4.2 ZIOPHARM Oncology Business Overview
  22. 6.4.3 ZIOPHARM Oncology Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 ZIOPHARM Oncology Neoantigen Vaccine Product Portfolio
  24. 6.4.5 ZIOPHARM Oncology Recent Developments
  25. 6.5 Vaximm AG
  26. 6.5.1 Vaximm AG Company Information
  27. 6.5.2 Vaximm AG Business Overview
  28. 6.5.3 Vaximm AG Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Vaximm AG Neoantigen Vaccine Product Portfolio
  30. 6.5.5 Vaximm AG Recent Developments
  31. 6.6 Vaccibody AS
  32. 6.6.1 Vaccibody AS Company Information
  33. 6.6.2 Vaccibody AS Business Overview
  34. 6.6.3 Vaccibody AS Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Vaccibody AS Neoantigen Vaccine Product Portfolio
  36. 6.6.5 Vaccibody AS Recent Developments
  37. 6.7 Roche Holding AG
  38. 6.7.1 Roche Holding AG Company Information
  39. 6.7.2 Roche Holding AG Business Overview
  40. 6.7.3 Roche Holding AG Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Roche Holding AG Neoantigen Vaccine Product Portfolio
  42. 6.7.5 Roche Holding AG Recent Developments
  43. 6.8 OSE Immunotherapeutics
  44. 6.8.1 OSE Immunotherapeutics Company Information
  45. 6.8.2 OSE Immunotherapeutics Business Overview
  46. 6.8.3 OSE Immunotherapeutics Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 OSE Immunotherapeutics Neoantigen Vaccine Product Portfolio
  48. 6.8.5 OSE Immunotherapeutics Recent Developments
  49. 6.9 Novogene
  50. 6.9.1 Novogene Company Information
  51. 6.9.2 Novogene Business Overview
  52. 6.9.3 Novogene Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Novogene Neoantigen Vaccine Product Portfolio
  54. 6.9.5 Novogene Recent Developments
  55. 6.10 Nouscom
  56. 6.10.1 Nouscom Company Information
  57. 6.10.2 Nouscom Business Overview
  58. 6.10.3 Nouscom Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Nouscom Neoantigen Vaccine Product Portfolio
  60. 6.10.5 Nouscom Recent Developments
  61. 6.11 Moderna
  62. 6.11.1 Moderna Company Information
  63. 6.11.2 Moderna Business Overview
  64. 6.11.3 Moderna Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Moderna Neoantigen Vaccine Product Portfolio
  66. 6.11.5 Moderna Recent Developments
  67. 6.12 Medigene AG
  68. 6.12.1 Medigene AG Company Information
  69. 6.12.2 Medigene AG Business Overview
  70. 6.12.3 Medigene AG Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Medigene AG Neoantigen Vaccine Product Portfolio
  72. 6.12.5 Medigene AG Recent Developments
  73. 6.13 ISA Pharmaceuticals
  74. 6.13.1 ISA Pharmaceuticals Company Information
  75. 6.13.2 ISA Pharmaceuticals Business Overview
  76. 6.13.3 ISA Pharmaceuticals Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 ISA Pharmaceuticals Neoantigen Vaccine Product Portfolio
  78. 6.13.5 ISA Pharmaceuticals Recent Developments
  79. 6.14 Gritstone Bio
  80. 6.14.1 Gritstone Bio Company Information
  81. 6.14.2 Gritstone Bio Business Overview
  82. 6.14.3 Gritstone Bio Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Gritstone Bio Neoantigen Vaccine Product Portfolio
  84. 6.14.5 Gritstone Bio Recent Developments
  85. 6.15 Genocea Biosciences Inc
  86. 6.15.1 Genocea Biosciences Inc Company Information
  87. 6.15.2 Genocea Biosciences Inc Business Overview
  88. 6.15.3 Genocea Biosciences Inc Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Genocea Biosciences Inc Neoantigen Vaccine Product Portfolio
  90. 6.15.5 Genocea Biosciences Inc Recent Developments
  91. 6.16 BrightPath Biotherapeutics
  92. 6.16.1 BrightPath Biotherapeutics Company Information
  93. 6.16.2 BrightPath Biotherapeutics Business Overview
  94. 6.16.3 BrightPath Biotherapeutics Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 BrightPath Biotherapeutics Neoantigen Vaccine Product Portfolio
  96. 6.16.5 BrightPath Biotherapeutics Recent Developments
  97. 6.17 BioNTech
  98. 6.17.1 BioNTech Company Information
  99. 6.17.2 BioNTech Business Overview
  100. 6.17.3 BioNTech Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 BioNTech Neoantigen Vaccine Product Portfolio
  102. 6.17.5 BioNTech Recent Developments
  103. 6.18 Avidea Technologies
  104. 6.18.1 Avidea Technologies Company Information
  105. 6.18.2 Avidea Technologies Business Overview
  106. 6.18.3 Avidea Technologies Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Avidea Technologies Neoantigen Vaccine Product Portfolio
  108. 6.18.5 Avidea Technologies Recent Developments
  109. 6.19 Agenus Inc
  110. 6.19.1 Agenus Inc Company Information
  111. 6.19.2 Agenus Inc Business Overview
  112. 6.19.3 Agenus Inc Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Agenus Inc Neoantigen Vaccine Product Portfolio
  114. 6.19.5 Agenus Inc Recent Developments
  115. 6.20 Advaxis
  116. 6.20.1 Advaxis Company Information
  117. 6.20.2 Advaxis Business Overview
  118. 6.20.3 Advaxis Neoantigen Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Advaxis Neoantigen Vaccine Product Portfolio
  120. 6.20.5 Advaxis Recent Developments
7 North America
  1. 7.1 North America Neoantigen Vaccine Market Size (2021-2032)
  2. 7.2 North America Neoantigen Vaccine Market Size by Type
  3. 7.2.1 North America Neoantigen Vaccine Market Size by Type (2021-2026)
  4. 7.2.2 North America Neoantigen Vaccine Market Size by Type (2027-2032)
  5. 7.2.3 North America Neoantigen Vaccine Market Share by Type (2021-2032)
  6. 7.3 North America Neoantigen Vaccine Market Size by Application
  7. 7.3.1 North America Neoantigen Vaccine Market Size by Application (2021-2026)
  8. 7.3.2 North America Neoantigen Vaccine Market Size by Application (2027-2032)
  9. 7.3.3 North America Neoantigen Vaccine Market Share by Application (2021-2032)
  10. 7.4 North America Neoantigen Vaccine Market Size by Country
  11. 7.4.1 North America Neoantigen Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Neoantigen Vaccine Market Size by Country (2021-2026)
  13. 7.4.3 North America Neoantigen Vaccine Market Size by Country (2027-2032)
  14. 7.4.4 North America Neoantigen Vaccine Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Neoantigen Vaccine Market Size (2021-2032)
  2. 8.2 Europe Neoantigen Vaccine Market Size by Type
  3. 8.2.1 Europe Neoantigen Vaccine Market Size by Type (2021-2026)
  4. 8.2.2 Europe Neoantigen Vaccine Market Size by Type (2027-2032)
  5. 8.2.3 Europe Neoantigen Vaccine Market Share by Type (2021-2032)
  6. 8.3 Europe Neoantigen Vaccine Market Size by Application
  7. 8.3.1 Europe Neoantigen Vaccine Market Size by Application (2021-2026)
  8. 8.3.2 Europe Neoantigen Vaccine Market Size by Application (2027-2032)
  9. 8.3.3 Europe Neoantigen Vaccine Market Share by Application (2021-2032)
  10. 8.4 Europe Neoantigen Vaccine Market Size by Country
  11. 8.4.1 Europe Neoantigen Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Neoantigen Vaccine Market Size by Country (2021-2026)
  13. 8.4.3 Europe Neoantigen Vaccine Market Size by Country (2027-2032)
  14. 8.4.4 Europe Neoantigen Vaccine Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Neoantigen Vaccine Market Size (2021-2032)
  2. 9.2 China Neoantigen Vaccine Market Size by Type
  3. 9.2.1 China Neoantigen Vaccine Market Size by Type (2021-2026)
  4. 9.2.2 China Neoantigen Vaccine Market Size by Type (2027-2032)
  5. 9.2.3 China Neoantigen Vaccine Market Share by Type (2021-2032)
  6. 9.3 China Neoantigen Vaccine Market Size by Application
  7. 9.3.1 China Neoantigen Vaccine Market Size by Application (2021-2026)
  8. 9.3.2 China Neoantigen Vaccine Market Size by Application (2027-2032)
  9. 9.3.3 China Neoantigen Vaccine Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Neoantigen Vaccine Market Size (2021-2032)
  2. 10.2 Asia Neoantigen Vaccine Market Size by Type
  3. 10.2.1 Asia Neoantigen Vaccine Market Size by Type (2021-2026)
  4. 10.2.2 Asia Neoantigen Vaccine Market Size by Type (2027-2032)
  5. 10.2.3 Asia Neoantigen Vaccine Market Share by Type (2021-2032)
  6. 10.3 Asia Neoantigen Vaccine Market Size by Application
  7. 10.3.1 Asia Neoantigen Vaccine Market Size by Application (2021-2026)
  8. 10.3.2 Asia Neoantigen Vaccine Market Size by Application (2027-2032)
  9. 10.3.3 Asia Neoantigen Vaccine Market Share by Application (2021-2032)
  10. 10.4 Asia Neoantigen Vaccine Market Size by Country
  11. 10.4.1 Asia Neoantigen Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Neoantigen Vaccine Market Size by Country (2021-2026)
  13. 10.4.3 Asia Neoantigen Vaccine Market Size by Country (2027-2032)
  14. 10.4.4 Asia Neoantigen Vaccine Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Neoantigen Vaccine Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Neoantigen Vaccine Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Neoantigen Vaccine Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Neoantigen Vaccine Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Neoantigen Vaccine Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Neoantigen Vaccine Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Neoantigen Vaccine Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Neoantigen Vaccine Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Neoantigen Vaccine Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Neoantigen Vaccine Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Neoantigen Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Neoantigen Vaccine Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Neoantigen Vaccine Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Neoantigen Vaccine Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst